-
Mashup Score: 6
Delineation of cancer cell spreading from primary bone metastasis by an evolving barcode system highlights the impact of the bone microenvironment in shaping secondary metastasis through mechanisms distinct from clonal selection.
Source: CellCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 5
Recent progress in cancer immunotherapy highlights the power of the immune system to control tumors, although a small patient subset responds to current immunotherapies. Additional approaches to mobilize antitumor immunity are required to overcome primary and acquired resistance to immunotherapy such as immune checkpoint blockade (ICB). Emerging evidence shows that targeting epigenetic elements…
Source: Trends in ImmunologyCategories: Allergy-Immunology, Latest HeadlinesTweet-
Read the Review @TrendsImmuno on Overcoming Immune #Checkpoint Blockade #Resistance via #EZH2 #Inhibition by Hye-Jung Kim, Harvey Cantor & Kat Cosmopoulos #AACR21 https://t.co/povxOddUtC https://t.co/37XevYg1lT
-
-
Mashup Score: 3The Polycomb landscape in mouse development - 3 year(s) ago
Polycomb-group proteins assemble into two primary complexes—Polycomb repressive complex (PRC) 1 and 2—that safeguard cell fate by repressing gene transcription. Two new studies explore the PRC1 landscape during the transition from gametes to embryos in mice, thus providing insight into the intergenerational transmission of epigenetic information and gene regulation dynamics as embryos prepare for…
Source: Nature GeneticsCategories: Hem/Oncs, Latest HeadlinesTweet-
Ok for those who do #mouse and #polycomb #Ezh2 work 🤩💥💥 The Polycomb landscape in mouse development | Nature Genetics @NatureGenet https://t.co/eaMr6hPquH
-
-
Mashup Score: 1EZH2-Targeted Therapies in Cancer: Hype or a Reality - 3 year(s) ago
Next-generation genomic sequencing has identified multiple novel molecular alterations in cancer. Since the identification of DNA methylation and histone modification, it has become evident that genes encoding epigenetic modifiers that locally and globally regulate gene expression play a crucial role in normal development and cancer progression. The histone methyltransferase enhancer of zeste…
Source: Cancer ResearchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Epigenetic enzyme histone methyltransferase enhancer of zeste homolog 2 #EZH2 is overexpressed in #cancer. Eich et al highlight advances in targeting EZH2 and discuss future directions of this therapeutic subclass in this #ReviewArticle. @Varambally_S https://t.co/qzP3BPehgP https://t.co/Ictv5UD9Ax
-
-
Mashup Score: 1EZH2 inhibition for epithelioid sarcoma and follicular lymphoma - 3 year(s) ago
Genome-driven precision oncology culminating from the human genome project, the availability of clinical next-generation sequencing, and the development of kinase inhibitors has transformed our understanding of the landscape of cancers driven by multiple oncogenes (eg, KIT, BRAF, EGFR, and RET). Yet, comprehensive genomic profiling has still not impacted the standard-of-care therapies for most…
Source: The Lancet OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
EZH2 inhibition for epithelioid sarcoma and follicular lymphoma @TheLancetOncol #sarcoma #lymphoma #EZH2 https://t.co/8vwOcjZ5Io
-
-
Mashup Score: 1Entinostat plus pembrolizumab in patients with metastatic NSCLC previously treated with anti-PD-(L)1 therapy - 3 year(s) ago
Purpose: New therapies are needed to treat immune checkpoint inhibitor-resistant non-small cell lung cancer (NSCLC) and identify biomarkers to personalize treatment. Epigenetic therapies, including histone deacetylase inhibitors, may synergize with programmed cell death-1 (PD-1)blockade to overcome resistance. We report outcomes in patients with anti-PD-(L)1-resistant/refractory NSCLC treated…
Source: Clinical Cancer ResearchCategories: Hem/Oncs, Latest HeadlinesTweet-
Important-great to see epigenetic Rx helping in combo but raises the question about the ‘right’ epigenetic target? @CSCancerCare @EdwinPosadasMD @ReckampK #Ezh2 https://t.co/MOGmmbikuZ
-
-
Mashup Score: 0
In our exclusive interview, Dr. Leonard discusses the FDA approval of tazemetostat in patients with relapsed/refractory follicular lymphoma whose tumors are EZH2 positive, as well as those with relapsed/refractory follicular lymphoma who have no other available satisfactory treatment options, and the benefits of providing another agent for this subset of patients.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ICYMI: Dr. Leonard discusses the FDA approval of #tazemetostat in patients with relapsed/refractory follicular lymphoma whose tumors are #EZH2 positive @WeillCornell @JohnPLeonardMD https://t.co/L77wPhPZUp https://t.co/LfCT3SOc4v
-
-
Mashup Score: 0EZH2-Targeted Therapies in Cancer: Hype or a Reality - 4 year(s) ago
Next-generation genomic sequencing has identified multiple novel molecular alterations in cancer. Since the identification of DNA methylation and histone modification, it has become evident that genes encoding epigenetic modifiers that locally and globally regulate gene expression play a crucial role in normal development and cancer progression. The histone methyltransferase enhancer of zeste…
Source: Cancer ResearchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ReviewArticle: Epigenetic enzyme histone methyltransferase enhancer of zeste homolog 2 #EZH2 is overexpressed in #cancer. Eich et al highlight advances in targeting EZH2 and discuss future directions of this therapeutic subclass. @Varambally_S https://t.co/LQtGbLX5IB https://t.co/Jo5fK1eL6e
-
-
Mashup Score: 0
In our exclusive interview, Dr. Leonard discusses the FDA approval of tazemetostat in patients with relapsed/refractory follicular lymphoma whose tumors are EZH2 positive, as well as those with relapsed/refractory follicular lymphoma who have no other available satisfactory treatment options, and the benefits of providing another agent for this subset of patients.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ICYMI: Dr. Leonard discusses the FDA approval of #tazemetostat in patients with relapsed/refractory follicular lymphoma whose tumors are #EZH2 positive @WeillCornell @JohnPLeonardMD https://t.co/L77wPhPZUp https://t.co/XPcZkz7ZxM
-
-
Mashup Score: 0
Tazemetostat produced an overall response rate of 15% and median overall survival of 19.0 months.
Source: Cancer DiscoveryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ResearchWatch: Epithelioid #Sarcoma responds to the oral #EZH2 inhibitor tazemetostat. @sloan_kettering #ClinicalTrial https://t.co/AZf8NStp5y https://t.co/5YY3GJRCNn
-
#EZH2 at it again The bone microenvironment invigorates metastatic seeds for further dissemination: Cell https://t.co/qkRPGyLUnf